# A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

> **NCT04660344** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 761 (actual)

## Conditions studied

- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Atezolizumab
- **OTHER:** Placebo
- **DEVICE:** Signatera

## Key facts

- **NCT ID:** NCT04660344
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-03
- **Primary completion:** 2025-06-15
- **Final completion:** 2026-10-01
- **Target enrollment:** 761 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04660344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04660344, "A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04660344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*